Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia

APMIS

Volumn 116, Issue 12, 2008, Pages 1058-1062

  Smolej, L ^a,c   Kasparova P ^b  

^a Department of Clinical Hematology ^*  (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Bone marrow biopsy; CD34; Chronic lymphocytic leukemia; Immunohistochemistry; Microvessel density; Neovascularization; Von Willebrand factor

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; MONOCLONAL ANTIBODY;

ANGIOGENESIS; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CELL DENSITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; MICROVASCULATURE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; BONE MARROW; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICROVESSELS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL; VON WILLEBRAND FACTOR;

EID: 58149186814     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00987.x     Document Type: Article

References (22)

1. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005 90 : 391 9.
2. Molica S, Vacca A, Levato D, Merchionne F, Ribatti D. Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res 2004 28 : 321 4.
3. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006 33 : 174 85.
4. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002 16 : 911 9.
5. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000 96 : 2240 5.
6. Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol 2001 113 : 400 6.
7. Molica S, Vitelli G, Levato D, Ricciotti A, Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer 2002 86 : 31 5.
8. Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 2003 12 : 167 71.
9. Smolej L, Maisnar V, Andrýs C, Pour L, Malý J. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica (Hradec Králové) 2005 48 : 57 8.
10. Smolej L, Andrys C, Pekova S, Schwarz J, Belada D, Zák P. Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia. Haematologica 2006 91 : 1432 3.
11. Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000 6 : 3111 6.
12. Niemoller K, Jakob C, Heider U, Zavrski I, Eucker J, Kaufmann O, et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003 129 : 234 8.
13. Korkolopoulou P, Gribabis DA, Kavantzas N, Angelopoulou MK, Siakantaris MP, Patsouris E, et al. A morphometric study of bone marrow angiogenesis in hairy cell leukaemia with clinicopathological correlations. Br J Haematol 2003 122 : 900 10.
14. Panteli K, Zagorianakou N, Bai M, Katsaraki A, Agnantis NJ, Bourantas K. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. Eur J Haematol 2004 72 : 410 5.
15. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000 14 : 1414 8.
16. Sezer O, Niemöller K, Jakob C, et al. Increased bone marrow angiogenesis is of prognostic relevance in patients with chronic lymphocytic leukemia. Blood 2001 98 : 361a (abstract).
17. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002 100 : 3344 51.
18. Wolowiec D, Wozniak Z, Potoczek S, Ganczarski G, Wrobel T, Kuliczkowski K, et al. Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia. Anal Quant Cytol Histol 2004 26 : 263 70.
19. Kašparová P, Smolej L. Angiogenesis in the bone marrow of patients with chronic lymphocytic leukemia. Cesk Patol 2007 43 : 50 8.
20. De Raeve HR, Vermeulen PB, Vanderkerken K, Harris AL, Van Marck E. Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance. Virchows Arch 2004 445 : 27 35.
21. Norrby K, Ridell B. Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and Factor VIII. APMIS 2003 111 : 483 9.
22. Pekova S, Markova J, Pajer P, Dvorak M, Cetkovsky P, Schwarz J. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn 2005 9 : 23 34.